Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Contineum Therapeutics (NASDAQ:CTNM) from a sell rating to a hold rating in a report issued on Sunday.

CTNM has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Wednesday, October 8th. Robert W. Baird reduced their target price on Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, November 24th. Royal Bank Of Canada dropped their price target on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating for the company in a research note on Friday, November 21st. Leerink Partners assumed coverage on shares of Contineum Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $22.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.40.

Contineum Therapeutics Stock Up 0.4%

NASDAQ CTNM opened at $12.31 on Friday. The company has a market capitalization of $359.21 million, a P/E ratio of -5.47 and a beta of 1.25. Contineum Therapeutics has a 12-month low of $3.35 and a 12-month high of $15.25. The firm has a 50-day moving average price of $11.31 and a two-hundred day moving average price of $9.01.

Contineum Therapeutics (NASDAQ:CTNM) last announced its earnings results on Thursday, October 30th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.13. Equities analysts expect that Contineum Therapeutics will post -2.01 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CTNM. Strs Ohio acquired a new stake in shares of Contineum Therapeutics in the 1st quarter valued at approximately $27,000. Bank of America Corp DE lifted its stake in Contineum Therapeutics by 500.0% in the 3rd quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock valued at $85,000 after purchasing an additional 6,030 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in Contineum Therapeutics in the second quarter valued at approximately $43,000. Marex Group plc bought a new stake in shares of Contineum Therapeutics during the second quarter worth $45,000. Finally, Bailard Inc. acquired a new position in shares of Contineum Therapeutics during the third quarter worth $145,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.